Marcus Vetter
Overview
Explore the profile of Marcus Vetter including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
62
Citations
1975
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Kappos E, Haas Y, Schulz A, Peters F, Savanthrapadian S, Stoffel J, et al.
BMJ Open
. 2025 Feb;
15(2):e090662.
PMID: 39961719
Introduction: Up to one-fifth of breast cancer survivors will develop chronic breast cancer-related lymphoedema (BCRL). To date, complex physical decongestion therapy (CDT) is the gold standard of treatment. However, it...
2.
Kurzeder C, Nguyen-Strauli B, Krol I, Ring A, Castro-Giner F, Nuesch M, et al.
Nat Med
. 2025 Jan;
PMID: 39856336
The presence of circulating tumor cell (CTC) clusters is associated with disease progression and reduced survival in a variety of cancer types. In breast cancer, preclinical studies showed that inhibitors...
3.
Ullrich F, Brockelmann P, Turki A, Khan A, Chiru E, Vetter M, et al.
J Immunother Cancer
. 2024 Dec;
12(12.
PMID: 39622581
The treatment landscape for lymphoma and multiple myeloma, which disproportionally affect older adults, has been transformed by the advent of T cell-mediated immunotherapies, including immune checkpoint inhibition, T cell-engaging bispecific...
4.
Petitat-Berli M, Knufinke M, Voegeli M, Sonderegger M, Seifert B, Chiru E, et al.
Int J Mol Sci
. 2024 Oct;
25(20).
PMID: 39457104
In the last two decades, next-generation sequencing (NGS) has facilitated enormous progress in cancer medicine, in both diagnosis and treatment. However, the usefulness of NGS in older cancer patients is...
5.
Cathomas M, Taha A, Kunst N, Burri E, Vetter M, Galli R, et al.
J Geriatr Oncol
. 2024 Sep;
15(8):102062.
PMID: 39270426
Introduction: Enhanced recovery after surgery (ERAS) is an established pathway to improve short-term outcomes in colorectal surgery. It is unclear whether the efficacy, feasibility, and safety of the ERAS protocol...
6.
Grasic Kuhar C, Geiger J, Schwab F, Heinzelmann-Schwartz V, Vetter M, Weber W, et al.
Cancers (Basel)
. 2024 Apr;
16(7).
PMID: 38610984
Neoadjuvant systemic treatment (NST) is the standard treatment for HER2+, triple-negative (TN), and highly proliferative luminal HER2- early breast cancer. Pathologic complete response (pCR) after NST is associated with improved...
7.
Zwimpfer T, Bilir E, Gasimli K, Cokan A, Bizzarri N, Razumova Z, et al.
Cancers (Basel)
. 2024 Mar;
16(6).
PMID: 38539490
Platinum and taxane chemotherapy is associated with the risk of hypersensitivity reactions (HSRs), which may require switching to less effective treatments. Desensitization to platinum and taxane HSRs can be used...
8.
Rudolf F, Baschong A, Bilecen D, Aceto N, Vetter M
Case Rep Oncol
. 2024 Feb;
17(1):277-282.
PMID: 38371170
Introduction: Pulmonary tumor thrombotic microangiopathy (PTTM) is a rare complication of metastatic carcinoma, which occurs in patients with pulmonary arterial hypertension, and is mostly fatal. Circulating tumor cell clusters have...
9.
Mizutani T, Cheung K, Hakobyan Y, Lane H, Decoster L, Karnakis T, et al.
J Geriatr Oncol
. 2024 Feb;
15(2):101709.
PMID: 38310661
Introduction: The Sustainable Development Goals of the United Nations include a commitment to "leave no one behind" as a universal goal. To achieve this in geriatric oncology (GO) worldwide, it...
10.
Chiru E, Oseledchyk A, Schoetzau A, Kurzeder C, Mosimann R, Vetter M, et al.
Diagnostics (Basel)
. 2024 Jan;
14(1).
PMID: 38201405
In patients with hormone receptor positive, human epidermal receptor 2 negative (HR+/HER2-) negative breast cancer (BC), the TAILORx study showed the benefit of adding chemotherapy (CHT) to endocrine therapy (ET)...